FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W100806778> ?p ?o ?g. }

• W100806778 abstract "Targeting of the BRAFV600 mutation has proven a highly effective treatment strategy for the subset of melanoma carrying this mutation. However, the majority (~60%) of patients with advanced melanoma do not carry this mutation and are not targetable by selective BRAF inhibitors. The rapidly evolving genetic landscape of melanoma has revealed that the vast majority of non-V600 BRAF mutant melanoma still express other genomic alterations that lead to MAP kinase pathway activation. The most frequent of these are activating mutations in the NRAS gene representing 1/3 of the non-V600 BRAF mutant melanoma or 15-20% overall. The other MAPkinase activating genetic alteration include NF1 loss of function, MAP2K1, C-RAF, K- or H-RAS, and alternate -non-V600 mutations in the BRAF gene. Therefore MEK inhibitors, ERK inhibitors, or even non-selective RAF inhibitors may represent effective therapeutic interventions. Early results in the NRAS mutant and non-NRAS or BRAF V600E mutant melanoma demonstrate clinical activity but likely not as robust as hoped. A trial with a MEK inhibitor (binmetinib) has demonstrated an unconfirmed objective response rate of approximately 20%. MEK inhibitors are also active against non-NRAS, non-BRAF V600 mutant melanoma including responses in those melanomas carrying mutations in BRAF gene outside of V600 codon.Genomic findings also demonstrate a high frequency of dysregulation of cell cycle regulatory proteins including genomic alterations in CDKN2A, CDK4, Cyclin D1, etc.This finding suggests a role for CDK4/6 inhibitors in the therapy of melanoma. Additionally, preclinical work has demonstrated the effectiveness of the combination of MEK inhibitors (trametinib, binimetinib) with CDK4/6 inhibitors (palbociclib, LEE011) in multiple mouse models of NRAS mutant melanoma. New, selective, and more effective CDK4/6 inhibitors have arrived in the clinic including palbociclib and LEE011 to name several, Based on this background clinical investigations have recently begun in non-BRAF V600 mutant melanomas with combination MEK inhibitor and CDK4/6 inhibitor treatment. While very early in their development, Binimetinib and LEE011 has already produced objective clinical responses in about 1/3 of NRAS mutant melanoma patients with another 1/3 demonstrating clinical responses not meeting RECIST 1.1 criteria. Most impressive is the rapid nature of these responses and in some cases accompanying relief from tumor-related symptoms. Early on some significant toxicities have been observed and alternate schedules are being explored. These regimens are also being evaluated in the non-NRAS mutant, non BRAF V600 mutant melanomas. As premature as these results are they still provide excitement that targeting mutations other than BRAFV600 is feasible and may provide hope for additional therapeutic options for the majority of melanoma patients." @default.
• W100806778 created "2016-06-24" @default.
• W100806778 creator A5040848764 @default.
• W100806778 date "2015-01-01" @default.
• W100806778 modified "2023-09-26" @default.
• W100806778 title "MEK + CDK4 a regimen for non-BRAF V6000 melanoma" @default.
• W100806778 doi "https://doi.org/10.1186/1479-5876-13-s1-k9" @default.
• W100806778 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4315259" @default.
• W100806778 hasPublicationYear "2015" @default.
• W100806778 type Work @default.
• W100806778 sameAs 100806778 @default.
• W100806778 citedByCount "3" @default.
• W100806778 countsByYear W1008067782017 @default.
• W100806778 countsByYear W1008067782018 @default.
• W100806778 countsByYear W1008067782021 @default.
• W100806778 crossrefType "journal-article" @default.
• W100806778 hasAuthorship W100806778A5040848764 @default.
• W100806778 hasBestOaLocation W1008067781 @default.
• W100806778 hasConcept C104317684 @default.
• W100806778 hasConcept C121608353 @default.
• W100806778 hasConcept C143065580 @default.
• W100806778 hasConcept C184235292 @default.
• W100806778 hasConcept C21790070 @default.
• W100806778 hasConcept C2776131300 @default.
• W100806778 hasConcept C2776470698 @default.
• W100806778 hasConcept C2777658100 @default.
• W100806778 hasConcept C2778472372 @default.
• W100806778 hasConcept C2778830669 @default.
• W100806778 hasConcept C2780265364 @default.
• W100806778 hasConcept C2781187634 @default.
• W100806778 hasConcept C2781249067 @default.
• W100806778 hasConcept C2994587330 @default.
• W100806778 hasConcept C501734568 @default.
• W100806778 hasConcept C502942594 @default.
• W100806778 hasConcept C54355233 @default.
• W100806778 hasConcept C57074206 @default.
• W100806778 hasConcept C71924100 @default.
• W100806778 hasConcept C86803240 @default.
• W100806778 hasConceptScore W100806778C104317684 @default.
• W100806778 hasConceptScore W100806778C121608353 @default.
• W100806778 hasConceptScore W100806778C143065580 @default.
• W100806778 hasConceptScore W100806778C184235292 @default.
• W100806778 hasConceptScore W100806778C21790070 @default.
• W100806778 hasConceptScore W100806778C2776131300 @default.
• W100806778 hasConceptScore W100806778C2776470698 @default.
• W100806778 hasConceptScore W100806778C2777658100 @default.
• W100806778 hasConceptScore W100806778C2778472372 @default.
• W100806778 hasConceptScore W100806778C2778830669 @default.
• W100806778 hasConceptScore W100806778C2780265364 @default.
• W100806778 hasConceptScore W100806778C2781187634 @default.
• W100806778 hasConceptScore W100806778C2781249067 @default.
• W100806778 hasConceptScore W100806778C2994587330 @default.
• W100806778 hasConceptScore W100806778C501734568 @default.
• W100806778 hasConceptScore W100806778C502942594 @default.
• W100806778 hasConceptScore W100806778C54355233 @default.
• W100806778 hasConceptScore W100806778C57074206 @default.
• W100806778 hasConceptScore W100806778C71924100 @default.
• W100806778 hasConceptScore W100806778C86803240 @default.
• W100806778 hasLocation W1008067781 @default.
• W100806778 hasLocation W1008067782 @default.
• W100806778 hasLocation W1008067783 @default.
• W100806778 hasOpenAccess W100806778 @default.
• W100806778 hasPrimaryLocation W1008067781 @default.
• W100806778 hasRelatedWork W1179952421 @default.
• W100806778 hasRelatedWork W1481134695 @default.
• W100806778 hasRelatedWork W1607072916 @default.
• W100806778 hasRelatedWork W1834308154 @default.
• W100806778 hasRelatedWork W2007853229 @default.
• W100806778 hasRelatedWork W2029761866 @default.
• W100806778 hasRelatedWork W2097280954 @default.
• W100806778 hasRelatedWork W2155862446 @default.
• W100806778 hasRelatedWork W2221230665 @default.
• W100806778 hasRelatedWork W2334888562 @default.
• W100806778 hasRelatedWork W2335844855 @default.
• W100806778 hasRelatedWork W2427873479 @default.
• W100806778 hasRelatedWork W2547428353 @default.
• W100806778 hasRelatedWork W2577806830 @default.
• W100806778 hasRelatedWork W2743762084 @default.
• W100806778 hasRelatedWork W2791141244 @default.
• W100806778 hasRelatedWork W2945742974 @default.
• W100806778 hasRelatedWork W3118180598 @default.
• W100806778 hasRelatedWork W3169668313 @default.
• W100806778 hasRelatedWork W37737972 @default.
• W100806778 isParatext "false" @default.
• W100806778 isRetracted "false" @default.
• W100806778 magId "100806778" @default.
• W100806778 workType "article" @default.